These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 8568798)

  • 1. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
    Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
    J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site.
    Barnette MS; Grous M; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1396-402. PubMed ID: 7791113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
    Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
    J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDP840: a novel inhibitor of PDE-4.
    Perry MJ; O'Connell J; Walker C; Crabbe T; Baldock D; Russell A; Lumb S; Huang Z; Howat D; Allen R; Merriman M; Walls J; Daniel T; Hughes B; Laliberte F; Higgs GA; Owens RJ
    Cell Biochem Biophys; 1998; 29(1-2):113-32. PubMed ID: 9631241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
    Jacobitz S; McLaughlin MM; Livi GP; Burman M; Torphy TJ
    Mol Pharmacol; 1996 Oct; 50(4):891-9. PubMed ID: 8863835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.
    Dal Piaz V; Giovannoni MP; Castellana C; Palacios JM; Beleta J; Doménech T; Segarra V
    J Med Chem; 1997 May; 40(10):1417-21. PubMed ID: 9154964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
    Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
    Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
    Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
    Crespo MI; Pagès L; Vega A; Segarra V; López M; Doménech T; Miralpeix M; Beleta J; Ryder H; Palacios JM
    J Med Chem; 1998 Oct; 41(21):4021-35. PubMed ID: 9767640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain.
    Hirose R; Manabe H; Nonaka H; Yanagawa K; Akuta K; Sato S; Ohshima E; Ichimura M
    Eur J Pharmacol; 2007 Nov; 573(1-3):93-9. PubMed ID: 17658510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate.
    Tian G; Rocque WJ; Wiseman JS; Thompson IZ; Holmes WD; Domanico PL; Stafford JA; Feldman PL; Luther MA
    Biochemistry; 1998 May; 37(19):6894-904. PubMed ID: 9578576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
    Kelly JJ; Barnes PJ; Giembycz MA
    Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of phosphodiesterase IV and intracellular calcium levels in human polymorphonuclear leukocytes.
    Villagrasa V; Navarrete C; Sanz C; Berto L; Perpiñá M; Cortijo J; Morcillo EJ
    Methods Find Exp Clin Pharmacol; 1996 May; 18(4):239-45. PubMed ID: 8803956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig.
    Harris AL; Connell MJ; Ferguson EW; Wallace AM; Gordon RJ; Pagani ED; Silver PJ
    J Pharmacol Exp Ther; 1989 Oct; 251(1):199-206. PubMed ID: 2552074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of relaxant responses evoked by a nitric oxide donor and by nonadrenergic, noncholinergic stimulation by isozyme-selective phosphodiesterase inhibitors in guinea pig trachea.
    Ellis JL; Conanan ND
    J Pharmacol Exp Ther; 1995 Mar; 272(3):997-1004. PubMed ID: 7891355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
    Christensen SB; Guider A; Forster CJ; Gleason JG; Bender PE; Karpinski JM; DeWolf WE; Barnette MS; Underwood DC; Griswold DE; Cieslinski LB; Burman M; Bochnowicz S; Osborn RR; Manning CD; Grous M; Hillegas LM; Bartus JO; Ryan MD; Eggleston DS; Haltiwanger RC; Torphy TJ
    J Med Chem; 1998 Mar; 41(6):821-35. PubMed ID: 9526558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
    Badger AM; Olivera DL; Esser KM
    Circ Shock; 1994 Dec; 44(4):188-95. PubMed ID: 7628060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.
    Underwood DC; Kotzer CJ; Bochnowicz S; Osborn RR; Luttmann MA; Hay DW; Torphy TJ
    J Pharmacol Exp Ther; 1994 Jul; 270(1):250-9. PubMed ID: 8035322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
    Kelly JJ; Barnes PJ; Giembycz MA
    Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.